Clinical trials: ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Ards
Duration of Prone Position in the Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).
The OMELETTE study is a randomised, controlled, unicentric, open-label study to prove the noninferiority of reduced prone position (PP) sessions (more tan 16 hours) versus prolonged PP (48 hours).
- Trial name
- OmeLEtte (NCT05012267)
- Testing
- 16-hour PP
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Ignacio Saez de la Fuente
Covid19, Corona Virus Infection
Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC)…
- Conditions
- Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS
- Trial name
- ULSC (NCT04494386)
- Testing
- Umbilical Cord Lining Stem Cells (ULSC)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Restem, LLC.
COVID-19 Pneumonia, ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Plasma SARS-CoV-2 RNA Levels in Critically Ill COVID-19 Patients
Retrospective, observationnal study. Evaluation of the association between plasmatic SARS-CoV-2 RNA and day 60 mortality in ICU adult COVID-19 patients.
- Trial name
- pRNA-COVID-ICU (NCT05115045)
- Testing
- plasmatic SARS-CoV-2 RNA quantification
- Where
- France
- Volunteers
- 122 people
- Sponsor
- Hopital of Melun
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Severe Sepsis
Symphony IL-6 Study in Patients at Risk of Severe Sepsis
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05665153
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bluejay Diagnostics, Inc.
ARDS Due to Disease Caused by SARS Co-V-2, Respiratory Compliance
Altered Respiratory Compliance Under Invasive Mechanical Ventilation in SARS-CoV-2 & Development of Respiratory Sequels
The goal is to study the association between the value of the compliance of the respiratory system at the first day of the initiation of invasive mechanical ventilation and the presence of respiratory sequelae at a distance from…
- Conditions
- ARDS Due to Disease Caused by SARS Co-V-2, Respiratory Compliance, Sequels of COVID
- Trial name
- COMPLI-QUO (NCT05721768)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
Mechanical Ventilation Complication, Hypoxemia
Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure
To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe…
- Conditions
- Mechanical Ventilation Complication, Hypoxemia, Acute Respiratory Distress Syndrome Due to COVID-19, COVID-19 Respiratory Infection
- Trial name
- REDEEM (NCT05562505)
- Testing
- Venovenous ECMO
- Where
- 7 sites in Australia, Germany
- Volunteers
- 140 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
ARDS Due to COVID-19
Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19
The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.
- Trial name
- NCT04568018
- Testing
- Surfactant
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biosurf LLC.
COVID-19, Respiratory Insufficiency
Telmisartan in Respiratory Failure Due to COVID-19
Rationale: The renin-angiotensin-aldosterone system (RAAS) dysregulation may play a central role in the pathophysiology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection associated acute lung injury (ALI)…
- Conditions
- COVID-19, Respiratory Insufficiency, Telmisartan, Respiratory Distress Syndrome, Adult
- Trial name
- STAR-COVID (NCT04510662)
- Testing
- Telmisartan
- Where
- Mexico
- Volunteers
- 66 people
- Sponsor
- Abraham Edgar Gracia-Ramos
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially…
- Trial name
- regARDS (NCT05027815)
- Testing
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jeffrey Bluestone
ARDS Due to Disease Caused by SARS Co-V-2
Prediction of Conversion From Vv-ECMO to Va-ECMO in COVID-19 Patients
In December 2019, cases of a novel lung disease, later referred to as COVID-19, were first reported in China. The virus SARS-CoV-2 was identified as the causative agent.
- Trial name
- ECMOPred-vvva (NCT05910996)
- Testing
- Conversion from vv-ECMO to va-ECMO
- Where
- Austria
- Volunteers
- 99 people
- Sponsor
- Kepler University Hospital
SARS CoV 2 Infection, Pneumonia
SP16 as a Therapeutic for COVID-19 Induced ARDS
This randomized, double-blind, placebo-controlled, Phase 1b study evaluates the safety and tolerability, and effects on cytokine and acute phase reactants of SP16, an anti-inflammatory drug, in patients with pneumonia due to…
- Trial name
- NCT05135624
- Testing
- SP16 (6mg), SP16 (12 mg)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Serpin Pharma, LLC
Respiratory Insufficiency
Pathophysiology of Gas Exchange and Time Course Changes in Spontaneously Breathing Patients With Acute Respiratory Failure Due to COVID-19. A Multicenter Prospective Study.
The pathophysiology of SARS-COV-2 related respiratory disease is still poorly understood, especially in its most severe form called acute respiratory distress syndrome (ARDS).
- Trial name
- COVAQ (NCT05392062)
- Testing
- Pathophysiology of gas exchange
- Where
- France
- Volunteers
- 59 people
- Sponsor
- CHU de Reims
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).
- Trial name
- NCT04366830
- Testing
- Remestemcel-L
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
ARDS Due to Disease Caused by SARS Co-V-2
Clinical Effects of Sivelestat Sodium on Improving ARDS in Patients With COVID-19
The goal of this retrospective multicentre cohort study is to examine the association between receipt of sivelestat and improvement in oxygenation among patients with acute respiratory distress syndrome (ARDS) induced by…
- Trial name
- NCT06218862
- Testing
- Sivelestat sodium, Control
- Where
- China
- Volunteers
- 387 people
- Sponsor
- The First Hospital of Jilin University
COVID-19, Acute Respiratory Distress Syndrome Due to COVID-19
Post-intensive Care Syndromes in Pregnant Patients With Respiratory Failure and COVID-19 Compared to Non-pregnant Patients With Respiratory Failure and COVID-19
The aim of this study is to characterize patients in the Post-Intensive-Care-Syndrome (PICS) outpatient clinic based on routine data and to evaluate their treatment outcome over the course of their treatment.
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome Due to COVID-19, Pregnancy Related
- Trial name
- NCT07051967
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
COVID-19, SARS-CoV 2
Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19
Randomized, double-blind, parallel, two-arms clinical trial to assess the efficacy and safety of 2 infusions of Wharton-Jelly mesenchymal stromal cells (day 1 and day 3, endovenously at 1E6cells/Kg per dose) in patients with…
- Conditions
- COVID-19, SARS-CoV 2, Adult Respiratory Distress Syndrome
- Trial name
- COVIDMES (NCT04390139)
- Testing
- XCEL-UMC-BETA
- Where
- 5 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Banc de Sang i Teixits
COVID19, Sepsis or Other Causes, Acute Respiratory Distress Syndrome
A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes
This is an open label phase II study of treatment with LEAF-4L6715 in patients who experience severe acute respiratory distress syndrome (ARDS) due to COVID-19, Sepsis or other Causes.
- Trial name
- NCT04378920
- Testing
- LEAF-4L6715
- Where
- 2 sites in France
- Volunteers
- 37 people
- Sponsor
- Institut de cancérologie Strasbourg Europe